OMCL

Omnicell, Inc. (OMCL) | Rumor.io

Omnicell

OMCL

Attention (50-day avg)0%

Attention rank (50-day avg)#3,208

Bullish sentiment (50-day avg)0%

Price to earnings ratio40

Market capitalization1.5B

Earnings per share0.84

Dividend yield (TTM)—

Revenue (annual)1.2B

Net income (annual)2.1M

Social

What share of all stock conversation is about OMCL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Apr 28

Omnicell, Inc. (OMCL) reported better-than-expected Q1 financial results, with revenue and EPS beating estimates.
The company issued Q2 sales guidance above estimates and raised its FY26 adjusted EPS guidance to $1.80 to $2.00.
Q1 print resulted in a 21.4% stock price increase, with revenue reaching $309.88M, up 14.91% YoY.

Generated by AI

Sentiment

Of the messages about OMCL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.45% +5.73
Bearish	—	—	—	4.55% -5.73

Apr 28

Omnicell's Q1 2026 earnings were a breakout quarter, with revenue growth of 15% year-over-year and nearly doubling non-GAAP EBITDA.
The company's successful navigation of the upgrade cycle for its XT Titan product is expected to drive cash flow over the next 5 years.
Omnicell's strong Q1 2026 earnings, with revenue up 15% and raised full-year guidance, are driving a breakout to new highs, with momentum targeting $57.34 and $58.83.

Generated by AI

Topics

Of the messages about OMCL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	22.22%	45.13%
Earnings	—	—	0%	23.52%
Technical Analysis	—	—	77.78%	4.24%
Analysts	—	—	0%	11.86%
Controversies	—	—	0%	0%
Macro	—	—	0%	15.25%

Earnings· Oct 25

Omnicell, Inc. (OMCL) reported earnings of $0.63 per share, beating the consensus estimate of $0.40.
The company's revenue for the quarter came in at $204.27 million, in line with expectations.
Omnicell guided Q4 earnings per share in line with estimates, with revenue also expected to match consensus.

Announcements· Apr 28

Omnicell reported Q1 2026 earnings with a revenue beat, exceeding market expectations, with sales of $309.9 million, up 14.9% YoY.
The company raised its full-year 2026 guidance, with non-GAAP EBITDA projected to be $153 million to $168 million and non-GAAP earnings per share to $1.80 to $2.00.
Omnicell's Q1 2026 performance was driven by strong platform demand and disciplined cost execution, with the stock surging to $44.59 (+18.50%) on the earnings surprise.

Technical Analysis· Apr 28

$OMCL has broken through the 4089.63 resistance level on high volume, with a potential target of 6001.33.
The breakout is confirmed by strong Q1 earnings, with a 15% revenue growth catalyst driving the momentum.
The stock's price surge indicates accelerating momentum, with potential targets of $57.34 and $58.83.

Generated by AI

Community

Of the messages about OMCL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	12.5%	4.19%
Newcomers	—	100%	87.5%	95.81%

Regulars· Nov 2

Omnicell's shares declined by over 30% after the company missed its topline guidance, with the stock also down in premarket trading.
Omnicell's third-quarter 2022 earnings report showed a non-GAAP EPS beat of $0.05, but revenue missed expectations by $15.12M, prompting the company to cut its FY 2022 guidance.
Omnicell's reported earnings of $1.00 per share beat the consensus estimate of $0.66, with the stock experiencing a delayed reaction to the earnings news.

Newcomers· Apr 28

Newcomers to the stock are optimistic about its earnings, citing a breakout quarter with rebounding margins and a strong start to 2026.
The stock's price has increased significantly, with a close of +20.9% and a market capitalization of $2.1B.
Investors are reminded to do your own research (DYOR) as daily market moves can reverse quickly.

Generated by AI

Omnicell trades around US$33.17 after a mixed share price record, and the key issue now is whether that level lines up with the cash the business can generate over time. With the stock showing both long slumps and shorter rebounds, investors are left asking how closely the current market value tracks the company’s underlying cash flows. Over the past 5 years the share price has fallen 77.7%, which puts the spotlight firmly on whether the long term cash flow potential still supports today’s...

7d agoYahoo Finance

Omnicell at Wells Fargo healthcare conference: betting on refresh cycle

20d agoInvesting.com

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

TraceLink, the world's largest Agentic Business Network for the life sciences and healthcare supply chain, today announced an integration between its Drug Supply Chain Security Act (DSCSA) compliance solution and the pharmacy inventory management systems of Omnicell, Inc. (Nasdaq: OMCL), a leading healthcare technology provider focused on empowering autonomous medication management. This integration is expected to enable hospitals and health systems to manage product verification, traceability,

26d agoYahoo Finance

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

FORT WORTH, Texas, August 31, 2026--Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

29d agoYahoo Finance

Omnicell: Offers Good Value, But Uncertainty Remains (NASDAQ:OMCL)

1mo agoSeeking Alpha

KeyBanc reiterates Omnicell stock rating on large pipeline growth

1mo agoInvesting.com

Also Discussed

Investors talking about OMCL also mention

#	Name	Attention
1	iShares Nasdaq-100 ex Top 30 ETFQNXT	0%0
2	Kforce Inc.KFRC	0%0
3	Zentek Ltd.ZTEK	0%0
4	Cactus Inc. Class A Common StockWHD	0%0
5	HealthEquity, Inc.HQY	0%new
6	Invesco NASDAQ Next Gen 100 ETFQQQJ	0%0
7	Resolute Holdings Management, Inc.RHLD	0%0
8	Citi Trends Inc.CTRN	0%0
9	Evolent Health IncEVH	0%0
10	The Bancorp, Inc.TBBK	0%new

Omnicell, Inc.

Healthcare
Health Information Services

Omnicell, Inc. is a healthcare technology company that provides medication management solutions and adherence tools for hospitals, health systems, retail pharmacies, and other care settings. Omnicell’s portfolio includes automated dispensing systems, central pharmacy automation, robotic dispensing, IV compounding, inventory management software, and point-of-care solutions designed to streamline medication workflows and support safer medication handling. The company also offers patient engagement and medication adherence tools through its EnlivenHealth brand, helping pharmacies and providers manage prescriptions, packaging, and communication more efficiently. Omnicell’s products and services are used across inpatient, outpatient, post-acute, and retail environments, where they support clinical teams with automation, analytics, and workflow integration. The company plays a notable role in healthcare operations by helping organizations improve medication management across the care continuum.

Website

Location

4220 North Freeway

Fort Worth, TX, 76137

United States

Social

What share of all stock conversation is about OMCL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% 0	0% +0

Apr 28

Omnicell, Inc. (OMCL) reported better-than-expected Q1 financial results, with revenue and EPS beating estimates.
The company issued Q2 sales guidance above estimates and raised its FY26 adjusted EPS guidance to $1.80 to $2.00.
Q1 print resulted in a 21.4% stock price increase, with revenue reaching $309.88M, up 14.91% YoY.

Generated by AI

Sentiment

Of the messages about OMCL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.45% +5.73
Bearish	—	—	—	4.55% -5.73

Apr 28

Omnicell's Q1 2026 earnings were a breakout quarter, with revenue growth of 15% year-over-year and nearly doubling non-GAAP EBITDA.
The company's successful navigation of the upgrade cycle for its XT Titan product is expected to drive cash flow over the next 5 years.
Omnicell's strong Q1 2026 earnings, with revenue up 15% and raised full-year guidance, are driving a breakout to new highs, with momentum targeting $57.34 and $58.83.

Generated by AI

Topics

Of the messages about OMCL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	22.22%	45.13%
Earnings	—	—	0%	23.52%
Technical Analysis	—	—	77.78%	4.24%
Analysts	—	—	0%	11.86%
Controversies	—	—	0%	0%
Macro	—	—	0%	15.25%

Earnings· Oct 25

Omnicell, Inc. (OMCL) reported earnings of $0.63 per share, beating the consensus estimate of $0.40.
The company's revenue for the quarter came in at $204.27 million, in line with expectations.
Omnicell guided Q4 earnings per share in line with estimates, with revenue also expected to match consensus.

Announcements· Apr 28

Omnicell reported Q1 2026 earnings with a revenue beat, exceeding market expectations, with sales of $309.9 million, up 14.9% YoY.
The company raised its full-year 2026 guidance, with non-GAAP EBITDA projected to be $153 million to $168 million and non-GAAP earnings per share to $1.80 to $2.00.
Omnicell's Q1 2026 performance was driven by strong platform demand and disciplined cost execution, with the stock surging to $44.59 (+18.50%) on the earnings surprise.

Technical Analysis· Apr 28

$OMCL has broken through the 4089.63 resistance level on high volume, with a potential target of 6001.33.
The breakout is confirmed by strong Q1 earnings, with a 15% revenue growth catalyst driving the momentum.
The stock's price surge indicates accelerating momentum, with potential targets of $57.34 and $58.83.

Generated by AI

Community

Of the messages about OMCL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	12.5%	4.19%
Newcomers	—	100%	87.5%	95.81%

Regulars· Nov 2

Omnicell's shares declined by over 30% after the company missed its topline guidance, with the stock also down in premarket trading.
Omnicell's third-quarter 2022 earnings report showed a non-GAAP EPS beat of $0.05, but revenue missed expectations by $15.12M, prompting the company to cut its FY 2022 guidance.
Omnicell's reported earnings of $1.00 per share beat the consensus estimate of $0.66, with the stock experiencing a delayed reaction to the earnings news.

Newcomers· Apr 28

Newcomers to the stock are optimistic about its earnings, citing a breakout quarter with rebounding margins and a strong start to 2026.
The stock's price has increased significantly, with a close of +20.9% and a market capitalization of $2.1B.
Investors are reminded to do your own research (DYOR) as daily market moves can reverse quickly.

Generated by AI

Omnicell

Social

Apr 28

Apr 28

Earnings· Oct 25

Announcements· Apr 28

Technical Analysis· Apr 28

Regulars· Nov 2

Newcomers· Apr 28

Omnicell (OMCL) Stock Trades Below Fair Value After A 78% Slump

Omnicell at Wells Fargo healthcare conference: betting on refresh cycle

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

Omnicell: Offers Good Value, But Uncertainty Remains (NASDAQ:OMCL)

KeyBanc reiterates Omnicell stock rating on large pipeline growth

Also Discussed

Omnicell, Inc.

Company Information

Location

Omnicell (OMCL) Stock Trades Below Fair Value After A 78% Slump

Omnicell at Wells Fargo healthcare conference: betting on refresh cycle

TraceLink and Omnicell Integrate DSCSA Compliance Solution into Hospital Pharmacy Operations

Omnicell to Present at the Wells Fargo 21st Annual Healthcare Conference

Omnicell: Offers Good Value, But Uncertainty Remains (NASDAQ:OMCL)

KeyBanc reiterates Omnicell stock rating on large pipeline growth

Also Discussed

Social

Apr 28

Apr 28

Earnings· Oct 25

Announcements· Apr 28

Technical Analysis· Apr 28

Regulars· Nov 2

Newcomers· Apr 28